Drug
Iloperidone
Iloperidone: highest development phase Post-Market, developed by Vanda Pharmaceuticals. 7 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Vanda Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Iloperidone NCT05648591 | Post-Market | Schizophrenia |
| Iloperidone NCT01291511 | Phase 3 | Schizophrenia |
| iloperidone NCT06961968 | Phase 3 | Schizophrenia |
| Iloperidone NCT00254202 | Phase 3 | Schizophrenia |
| iloperidone NCT07090161 | Phase 2 | Hypertension |
| Iloperidone NCT04712734 | Phase 1 | Schizophrenia |
| iloperidone (oral tablet) NCT01495169 | Phase 1 | Safety and Tolerability of Iloperidone |
Latest
Follow Iloperidone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.